Mylan Laboratories Limited — Gliclazide Exporter Profile
Indian Pharmaceutical Exporter · #1 for Gliclazide · $6.7M export value · DGFT Verified
Mylan Laboratories Limited is the #1 Indian exporter of Gliclazide with $6.7M in export value and 133 verified shipments. Mylan Laboratories Limited holds a 3.5% market share in Gliclazide exports across 7 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.
Mylan Laboratories Limited — Gliclazide Export Profile: Buyers & Destinations
Where Does Mylan Laboratories Limited Export Gliclazide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| HUNGARY | $1.7M | 43 | 40.3% |
| NETHERLANDS | $895.9K | 26 | 21.2% |
| FRANCE | $895.1K | 36 | 21.2% |
| SOUTH AFRICA | $344.4K | 14 | 8.1% |
| CANADA | $260.6K | 7 | 6.2% |
| AUSTRALIA | $85.3K | 6 | 2.0% |
| HONG KONG | $42.9K | 1 | 1.0% |
Mylan Laboratories Limited exports Gliclazide to 7 countries. The largest destination is HUNGARY accounting for 40.3% of Mylan Laboratories Limited's Gliclazide shipments, followed by NETHERLANDS (21.2%) and FRANCE (21.2%). These destinations reflect Mylan Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Gliclazide from Mylan Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN HUNGARY KFT, | HUNGARY | $878.4K | 21 |
| MYLAN HUNGARY KFT | HUNGARY | $585.1K | 17 |
| MYLAN B V | NETHERLANDS | $308.4K | 9 |
| CSP VIATRIS SANTE AT CSP- LABO, | FRANCE | $297.6K | 8 |
| CSP VIATRIS SANT? AT CSP- LAB, | FRANCE | $280.0K | 12 |
| MYLAN HUNGARY KFT MYLAN U | HUNGARY | $150.0K | 3 |
| MYLAN B V C | NETHERLANDS | $144.5K | 3 |
| CSP | FRANCE | $123.9K | 3 |
| CSP VIATRIS SANTE AT CSP- LAB, | FRANCE | $106.1K | 6 |
| MYLAN B.V. | NETHERLANDS | $100.2K | 3 |
Mylan Laboratories Limited supplies Gliclazide to 33 buyers globally. The largest buyer is MYLAN HUNGARY KFT, (HUNGARY), followed by MYLAN HUNGARY KFT (HUNGARY) and MYLAN B V (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Gliclazide Export Value and How Much Does Mylan Laboratories Limited Contribute?
India exported $68.5M worth of Gliclazide through 3,830 shipments from 238 suppliers to 109 countries, serving 643 buyers globally. Mylan Laboratories Limited contributes $6.7M to this total, accounting for 3.5% of India's Gliclazide exports. Mylan Laboratories Limited ships Gliclazide to 7 countries through 33 buyers.
What Is the Average Shipment Value for Mylan Laboratories Limited's Gliclazide Exports?
Mylan Laboratories Limited's average Gliclazide shipment value is $50.0K per consignment, based on 133 shipments totaling $6.7M. The largest destination is HUNGARY (40.3% of Mylan Laboratories Limited's Gliclazide exports).
How Does Mylan Laboratories Limited Compare to Other Indian Gliclazide Exporters?
Mylan Laboratories Limited ranks #1 among 238 Indian Gliclazide exporters with a 3.5% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($15.1M), MICRO LABS LIMITED ($7.6M), IPCA LABORATORIES LIMITED ($7.3M). Mylan Laboratories Limited processed 133 shipments to 7 destination countries.
What Gliclazide Formulations Does Mylan Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| GLICLAZIDE MODIFIED RELEASE TABLETS 30 M | $595.6K | 13 |
| GLICLAZIDE TAB PR 30MG EU (PACKS: 5000'S BSP) | $150.0K | 3 |
| GLICLAZIDE TABLETS 80 MG PACKS 4000SBSP | $144.5K | 3 |
| HARMLESS MEDICINES, GLICLAZIDE TAB PR 30MG EU | $113.0K | 3 |
| GLICLAZIDE TAB PR 30MG 180BT NL MY PACKS47732 | $100.2K | 3 |
| HARMLESS MEDICINES, GLICLAZIDE MODIFIED | $100.0K | 2 |
| GLICLAZIDE RETARD MYLAN 30 MG 180BT 281 | $100.0K | 2 |
| GLICLAZIDE TAB PR 60MG 30BT ZA MY PACKS50326 | $100.0K | 2 |
| GLICLAZIDE MODIFIED RELEASE TABLETS 30 MG PACKS 5000S BSP | $100.0K | 2 |
| GLICLAZIDE TABLETS 80 MG (PACKS 4000SBSP) | $100.0K | 2 |
Mylan Laboratories Limited exports 74 distinct Gliclazide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GLICLAZIDE MODIFIED RELEASE TABLETS 30 M with 13 shipments worth $595.6K.
How Does Mylan Laboratories Limited Compare to Nearest Gliclazide Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | MICRO LABS LIMITED | $7.6M | 205 | 17 | $37.2K |
| 5 | IPCA LABORATORIES LIMITED | $7.3M | 243 | 18 | $30.2K |
| 1 | MYLAN LABORATORIES LIMITED ★ | $6.7M | 133 | 7 | $50.0K |
| 6 | TORRENT PHARMACEUTICALS LTD | $6.1M | 217 | 3 | $28.1K |
| 7 | LUPIN LIMITED | $4.9M | 145 | 8 | $33.6K |
Mylan Laboratories Limited ranks #1 among 238 Indian Gliclazide exporters. Average shipment value of $50.0K compared to the market average of $287.6K. The closest competitors by value are MICRO LABS LIMITED and IPCA LABORATORIES LIMITED.
Which Indian Ports Ship Gliclazide Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 439 | 11.5% |
| SAHAR AIR | 375 | 9.8% |
| JNPT/ NHAVA SHEVA SEA | 323 | 8.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 247 | 6.4% |
| DELHI AIR | 229 | 6.0% |
| JNPT | 203 | 5.3% |
| DELHI AIR CARGO ACC (INDEL4) | 165 | 4.3% |
| CMA CGM LOGISTICS PARK ICD | 103 | 2.7% |
Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Gliclazide Exports
Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.
In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.
Mylan Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.
The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.
About Mylan Laboratories Limited
Mylan Laboratories Limited exports 91 products worth $634.8M. Beyond Gliclazide, top products include Tenofovir, Pantoprazole, Valsartan, Ritonavir, Trastuzumab. View the complete Mylan Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Gliclazide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Gliclazide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 133 individual customs records matching Mylan Laboratories Limited exporting Gliclazide, covering 74 formulations to 7 countries via 33 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 643+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Gliclazide Export Data from Mylan Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Laboratories Limited's Gliclazide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Laboratories Limited
Full Company Profile →
91 products · $634.8M total trade · 26 categories
Gliclazide Stats
Company Overview
Top Products by Mylan Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Gliclazide. For current shipment-level data, contact TransData Nexus.